- 1 Title: Epidemiology, clinical presentation and management of
- 2 COVID-19 associated Mucormycosis: A single center experience
- 3 from Pune, Western India.

- 5 Authors: Ameet Dravid MD ¹, Reema Kashiva MD ², Zafer Khan MD ³, Balasaheb Bande
- ³, Danish Memon MD ², Aparna Kodre MD ², Prashant Potdar MD ², Milind Mane MD ³,
- 7 Asir Tamboli MD ³, Vishal Pawar MD ³, Dattatraya Patil MD ³, Debashis Banerjee MD ³,
- 8 Kailas Bhoite ³, Akshay Shinde MD ³, Reshma Pharande MBBS ³, Suraj Kalyani MBBS ³,
- 9 Prathamesh Raut MBBS ³, Madhura Bapte MD ³, Charlotte Saldanha MD ³, Dinesh
- 10 Chandak MD ³, Fouzia Ajani MD ³, Anshul Mehta MBBS ², M Sateesh Reddy MBBS ²,
- 11 Krushnadas Bhayani MBBS ², S S Laxmi MBBS ², P D Vishnu MBBS ², Shipra Srivastava
- 12 MBBS ², Shubham Khandelwal MBBS ², Sailee More MBBS ², Atif Shakeel MBBS ²,
- Mohit Pawar MBBS ², Pranava Nande MBBS ², Amol Harshe MD ⁴, Sagar Kadam MD ⁵,
- Sudhir Hallikar MD ⁶, Nudrat Kamal MD ⁶, Danish Andrabi MD ⁶, Sachin Bodhale MD ⁷,
- 15 Akshay Raut BDS ⁸, Pushkar Gawande BDS ⁸, Ankush Bhandari BDS ⁸, Nilesh Wasmatkar
- MD 9, Adnanali Sarkar MD 9, Sangeeta Chandrashekhar MD 9, Pallavi Butiyani MD 9,
- 17 Geetanjali Akhade MD 9, Aditi Abnave MD 9, Chandrashekhar Raman MD 10, Siraj
- Basade MD 10 , Uma Mahajan M.Sc 11 , Gaurav Joshi MBA 12 , Dilip Mane MD 2
- 19 **Author Affiliations:**
- 20 1 Department of Infectious diseases and HIV/AIDS, Noble hospitals and Research Centre,
- 21 Pune, Maharashtra, India
- 22 2 Department of Medicine, Noble hospital and Research Centre, Pune, Maharashtra, India
- 23 3 Department of Critical Care Medicine, Noble hospital and Research Centre, Pune,
- 24 Maharashtra, India
- 25 4 Department of Pathology, Noble hospital and Research Centre, Pune, Maharashtra, India
- 5 Department of Radiology, Noble hospital and Research Centre, Pune, Maharashtra, India
- 27 6 Department of Otorhinolaryngology, Noble hospital and Research Centre, Pune,
- 28 Maharashtra, India

- 29 7 Department of Ophthalmology, Noble hospital and Research Centre, Pune, Maharashtra,
- 30 India
- 31 8 Department of Maxillo-facial surgery, Noble hospital and Research Centre, Pune,
- 32 Maharashtra, India
- 9 Department of Anesthesia, Noble hospital and Research Centre, Pune, Maharashtra, India
- 34 10- Department of Neurosurgery, Noble hospital and Research Centre, Pune, Maharashtra, India
- 35 11 Statistician, VMK Diagnostics private limited, Pune, Maharashtra, India.
- 36 12 Independent statistical consultant, Chicago, USA.

38

Email addresses of authors:

- 39 Ameet Dravid <u>ameet.dravid@gmail.com</u>, Reema Kashiva <u>reemakashiva@gmail.com</u>, Zafer
- 40 Khan <u>zafer_a_khan@yahoo.co.in</u>, Balasaheb Bande <u>drbandebd@hotmail.com</u>, Danish
- 41 Memon danish1331@yahoo.co.in, Aparna Kodre draparnankodre@gmail.com, Prashant
- 42 Potdar pashya2511@gmail.com, Milind Mane <u>drmilind.mane@gmail.com</u>, Asir Tamboli –
- 43 drasirtamboli@gmail.com, Vishal Pawar dr.vishal.d.pawar@gmail.com, Dattatraya Patil –
- 44 <u>drdattapatil05@gmail.com</u>, Debashis Banerjee <u>debaz2009@gmail.com</u>, Kailas Bhoite –
- 45 <u>kailasbhoite1978@gmail.com</u>, Akshay Shinde <u>dr.akshay7@gmail.com</u>, Reshma Pharande –
- reshma.pharande97@gmail.com, Suraj Kalyani surajkalyani@gmail.com, Prathamesh Raut –
- 47 rautlesh@gmail.com , Madhura Bapte madhuraparth@gmail.com, Charlotte Saldanha –
- charlotte2491@gmail.com, Dinesh Chandak dineshchandak444@gmail.com, Fouzia Ajani –
- 49 drfouziahirani@gmail.com, Anshul Mehta anshroks.25@gmail.com, M Sateesh Reddy –
- 50 satishat321@gmail.com , Krushnadas Bhayani kbhayani321@gmail.com, S S Laxmi –
- 51 <u>drsslakshmiatl@gmail.com</u>, P D Vishnu <u>p.d_vishnu@yahoo.co.in</u>, Shipra Srivastava –
- 52 srivastavashipra51@gmail.com, Shubham Khandelwal shubh.joyrider@gmail.com, Sailee
- More drsaileemore@gmail.com, Atif Shakeel khanaatif009@gmail.com, Mohit Pawar –
- 54 mohitpawar2915@gmail.com, Pranava Nande pranavanande4@gmail.com, Amol Harshe –
- 55 dramolh@yahoo.co.in , Sagar Kadam drsagarkadam@gmail.com , Sudhir Halikar –
- 56 <u>halikarsudhir@gmail.com</u>, Nudrat Kamal- <u>nudratkamal86@gmail.com</u>, Danish Andrabi –
- 57 danish_andrabi@yahoo.co.in, Sachin Bodhale drsrb1@gmail.com, Akshay Raut -
- akshayraut8@gmail.com, Pushkar Gawande gawandepushkar@gmail.com, Ankush Bhandari –

59	<u>dr.ankushbhandari@yahoo.com</u> , Nilesh Wasmatkar – <u>drnileshkw@gmail.com</u> , Adnanali Sarkar
60	$-\ \underline{adnansarkar2@gmail.com},\ Sangeeta\ Chandrashekhar\ -\ \underline{drsangeet15@rediffmail.com},\ Pallavi$
61	Butiyani – <u>pallavibutiyani@gmail.com</u> , Geetanjali Akhade – <u>dangat.geeta@gmail.com</u> , Aditi
62	$Abnave - \underline{abnave a \underline{diti@gmail.com}}, \ Chandrashekhar \ Raman - \underline{drshekhar71@hotmail.com}, \ Siraj$
63	Basade - siraj582@yahoo.com , Uma Mahajan - umasmahajan@gmail.com , Gaurav Joshi -
64	gaurav.arun.joshi@gmail.com, Dilip Mane – dileep.mane@yahoo.co.in.
65	
66	Corresponding Author – Ameet Dravid, Email – <u>ameet.dravid@gmail.com</u>
67	
68	Abbreviations:
69	Severe acute respiratory syndrome coronavirus 2 - SARS-CoV-2; coronavirus disease 2019-
70	COVID-19; World health organization – WHO; COVID-19 associated Mucormycosis – CAM;
71	C-reactive protein – CRP; lactate dehydrogenase – LDH; Interleukin – 6 - IL-6; Interferon
72	$Gamma \text{ - IFN-}\gamma; \text{ diabetes mellitus - DM; } Tocilizumab \text{ - TCZ; } cytokine \text{ release syndrome - CRS; }$
73	diabetic ketoacidosis - DKA; Rhino-orbito-cerebral mucormycosis - ROCM; Noble hospital and
74	Research Centre - NHRC; High resolution computerized tomography scan - HRCT ; oxygen
75	saturation - SpO_2 ; ratio of arterial partial pressure of oxygen to fraction of inspired oxygen-
76	$PaO_2/FiO_2; Functional\ endoscopic\ paranasal\ sinus\ surgery\ -\ FESS;\ Liposomal\ Amphotericin\ B\ -$
77	LAmB; reverse transcription PCR- RT-PCR; Intensive care unit - ICU; Central nervous system -
78	CNS; institutional review board - IRB; interquartile range - IQR; absolute neutrophil count -
79	ANC; absolute lymphocyte count - ALC; Intravenous - IV; acute respiratory distress syndrome
80	– ARDS.
81	
82	
83	
84	
85	
86	
87	
88	

Abstract:

- 90 Background: The second COVID-19 wave in India, triggered by the Delta variant, has been
- 91 associated with an unprecedented increase in cases of COVID-19 associated
- 92 Mucormycosis(CAM), mainly Rhino-orbito-cerebral mucormycosis(ROCM). The primary reason
- appears to be an unusual alignment of multiple risk factors in patients like prevalence of hypoxia,
- 94 uncontrolled diabetes mellitus, indiscriminate use of steroids, high iron levels and immune
- 95 dysfunction.
- 96 **Methods:** This retrospective cohort study was conducted at Noble hospital and Research Centre
- 97 (NHRC), Pune, Western India between 1st April 2020 and 1st August 2021 to identify patients
- admitted with CAM. The primary endpoint was incidence of all cause mortality due to CAM.
- 99 Secondary outcomes studied were need for mechanical ventilation and intensive care unit(ICU)
- admission. Baseline and time dependent risk factors significantly associated with death due to
- 101 CAM were identified by Relative risk estimation.
- 102 Results: 59 patients were diagnosed with Mucormycosis at NHRC (58 ROCM, 1 Renal
- 103 (disseminated) mucormycosis). Median age of the cohort was 52(IQR: 41,61) years and it
- included 20.3% females. Median duration from first positive COVID-19 RT PCR test to
- diagnosis of Mucormycosis was 17(IQR: 12,22) days. 90% patients were diabetic with 30%
- being newly diagnosed at the time of COVID-19 admission and 89% having uncontrolled sugar
- level (HbA1c > 7%). All patients were prescribed steroids during treatment for COVID-19. 56%
- patients were prescribed steroids for non-hypoxemic, mild COVID (irrational steroid therapy)
- while in 9%, steroids were indicated but were prescribed in inappropriately high dose. Majority
- of the patients were treated with a combination of surgical debridement(94%), intravenous
- Amphotericin B(91%) and concomitant oral Posoconazole therapy(95.4%). 74.6% patients were
- discharged after clinical and radiologic recovery while 25.4% (15 patients) died. On Relative risk
- analysis, CT severity score during COVID-19 admission ≥18 (p=0.017), presence of orbital
- symptoms(p=0.002), presence of diabetic ketoacidosis(p=0.011) and cerebral involvement by
- Mucor(p=0.0004) were associated with increased risk of death. Duration of Amphotericin B
- therapy of ≥ 21 days was associated with statistically significant reduction in mortality(p=0.002).

Conclusions: CAM is an uncommon, rapidly progressive, angioinvasive, opportunistic fungal infection which is fatal if left untreated. Combination of surgical debridement and antifungal therapy leads to clinical and radiologic improvement in majority of cases.

Introduction:

In December 2019, Wuhan city, the capital of Hubei province in China, became the centre of an outbreak of viral pneumonia. By Jan 7, 2020, scientists had isolated a novel RNA, beta coronavirus from these patients. It was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) due to its sequence homology with SARS-COV-1 [1]. The disease caused by SARS-COV-2 was later designated coronavirus disease 2019 (COVID-19) in February 2020, by World health organization (WHO) [2]. COVID-19 spread rapidly worldwide and India was no exception. By 1st August 2021, there have been more than 300 million infections and 0.4 million deaths due to COVID-19 in India [3]. With COVID-19, the incidence of secondary bacterial or fungal infections is 8%, with aspergillosis and candida being the most common fungi reported [4,5]. The second COVID wave in India (March 2021 – May 2021), triggered by the Delta variant, has also been associated with an unprecedented increase in the cases of COVID-19 associated Mucormycosis (CAM) [6,7]. Globally, the prevalence of mucormycosis varies from 0.005 to 1.7 per million population, while its prevalence is nearly 80 times higher (0.14 per 1000) in India as per a recent estimate of year 2019-2020 [7-9]. Thus, India already had the highest cases of mucormycosis in the world and the incidence increased exponentially during the second COVID wave. As of August 1st, 2021, 45,374 cases of CAM have been reported in India [6].

CAM is an uncommon, rapidly progressive, angio-invasive, commonly fatal, opportunistic fungal infection ^[9]. Unusual alignment of multiple risk factors could be associated with sudden spurt of CAM in India ^[10]. Dysregulated immune response in COVID-19 characterized by exuberant activation of innate immune system, elevation in systemic inflammatory markers (C-reactive protein (CRP), ferritin, lactate dehydrogenase (LDH) and D-dimer), aberrant pro-inflammatory cytokine secretion (Interleukin – 6 (IL-6), soluble IL-2 receptor [IL-2R], IL-10, TNF- α) by alveolar macrophages and depleted adaptive immune response (decline in CD4+ T cell, CD8+ T cell, Natural killer cell and decreased Interferon Gamma (IFN- γ) expression in CD4+ T cells) could be one of the factors predisposing individuals to CAM ^[11,12]. In these patients, the activation of antiviral immunity to SARS-CoV-2 may, paradoxically, potentiate an inflammatory phenotype and thus may favor secondary infections. In addition, India has the second largest population with diabetes mellitus (DM) in the world (77

million people with diabetes, with a nationwide prevalence of 7.3 %.)[13, 14]. SARS-CoV-2 has been shown to affect the beta cells of the pancreas, resulting in metabolic derangement, possibly causing diabetes mellitus [15]. Uncontrolled DM is a risk factor for both, COVID-19 and Mucormycosis. Steroids, namely Dexamethasone and Methylprednisolone have been extensively used to resolve hyperinflammation and inflammatory lung damage in severe COVID-19 [16-18]. But use of steroids can cause hyperglycemia, suppression of several polymorphonuclear (PMN) leucocyte functions, impairment of phagocytosis by resident macrophages, depletion of T cell immunity [10] and increase risk of Mucormycosis. Indiscriminate use of steroids in patients with mild or asymptomatic COVID-19 can be counter-productive and make the person susceptible to opportunistic fungi [19]. Use of immunomodulator therapy like Tocilizumab (TCZ, IL-6 receptor inhibitor) in combination with steroids for Cytokine release syndrome (CRS, cytokine storm) could further aggravate immunosuppression and facilitate breakthrough fungal infection [20]. Thus, the primary reason for this sudden increase in CAM in India appears to be germination of Mucorales spores in an ideal environment of low oxygen (hypoxia), high glucose (diabetes mellitus, new onset hyperglycemia, impaired fasting glucose or steroid-induced hyperglycemia), acidic environment^[10] (metabolic acidosis, diabetic ketoacidosis [DKA]), high iron levels (hyperferritinemia characteristic of COVID-19 leading to excess intracellular iron that generates reactive oxygen species and resultant death of cells with acidosis facilitating free iron release for mucor germination) [21,22] and immune dysfunction (mediated by Delta variant of SARS COV-2, steroid therapy or background co-morbidities).

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

The most common form of Mucormycosis seen in India during the COVID-19 pandemic was the Rhino-orbito-cerebral (ROCM) one but cases of pulmonary [7,23] or disseminated mucormycosis [24] have also been reported. Suspected ROCM requires urgent intervention, because of the often rapidly progressive and destructive nature of the infection. Delayed initiation of therapy is associated with increased mortality [25,26]. Despite treatment, case-fatality rates due to mucormycosis during the pre-COVID-19 pandemic era were already high, ranging from 32% to 70%, according to organ involvement [25,26]. However, in SARS-CoV-2 infection, the mortality maybe even higher. Maximizing survival rates requires rapid diagnostic and therapeutic intervention, including immediate involvement of a multidisciplinary medical, surgical, radiological, and laboratory-based team. Multiple case reports [27-50] and retrospective

cohort studies ^[7, 51-61] of CAM from India and other countries have already been published. However, detailed epidemiology, risk factor analysis, surgical and medical treatment administered, outcomes and complications (especially long-term complications) developing in these patients has been scarcely reported ^[7,52,57]. In addition, lack of imaging modalities in rural areas of India, inability to identify early symptoms by general practitioners, shortage of antifungal drugs (especially Liposomal Amphotericin B) during second COVID wave and inadequate number of specialists to perform complex endoscopic, orbital and skull base surgeries ^[7,10] posed a serious challenge in tackling rising ROCM cases in India and led to a high mortality in certain cohort studies ^[7,52]. As a result, we planned this retrospective observational cohort study aimed at understanding the epidemiology, clinical presentation, outcomes and long-term complications in patients with CAM admitted at our tertiary level hospital in Pune, Western India during the COVID-19 pandemic.

Methods:

Study Setting:

This retrospective cohort study was conducted at Noble hospital and Research Centre (NHRC), Pune, Western India. NHRC is a tertiary level private hospital designated for clinical management of COVID-19 patients and management of post COVID complications since 23rd March 2020. Pune is located in the state of Maharashtra, Western India and was one of the epicenters of COVID-19 epidemic in India. As of 1st August 2021, Maharashtra state has reported more than 6.3 million cases of COVID-19 and more than 133,000 deaths ^[3]. Till 1st August 2021, NHRC has admitted 5439 COVID-19 patients with 391 deaths. Maharashtra state has also reported more than 5000 cases of COVID-19 associated Mucormycosis (CAM) till 1st August 2021^[6].

NHRC provides clinical care, diagnostic and treatment services to patients at a subsidized cost. Data of all hospitalized patients is entered into an electronic database (Lifeline electronic database, Manorama infosystems, Kolhapur, India).

Study Population:

Patients were eligible for inclusion in this analysis if they were admitted to NHRC between 1st April 2020 and 1st August 2021 and were diagnosed with COVID-19 associated Mucormycosis (CAM). COVID-19 diagnosis was made in patients who tested positive for SARS

COV 2 RNA in respiratory specimens by reverse transcription PCR (RT-PCR) or a positive rapid antigen test. Mucormycosis was identified in patients having compatible clinical and radiologic manifestations and demonstration of fungi in the tissue or sterile body fluids by either direct microscopic visualization of broad ribbon-like aseptate hyphae (potassium hydroxide (KOH) mount or Calcofluor stain), culture isolation of Mucorales (Sabouraud dextrose agar) or Histopathology examination of affected tissue showing Mucor species (Hematoxylin and eosin, periodic acid Schiff, or Gomori methenamine silver stain) ^[9]. CAM was defined as development of Mucormycosis within 3 months of diagnosis of COVID-19.

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

Data was obtained from electronic health record of each individual admitted for treatment of CAM in NHRC by manual abstraction. It included hospitalization dates, demographics, comorbidities, severity of associated COVID-19 illness, treatment received for COVID-19 including steroids and immunomodulator therapy, presenting symptoms of Mucormycosis, clinical examination data, anatomic site of involvement, diagnostic modalities including microscopy, culture, or histopathology, laboratory investigation data (including inflammatory markers), microbiology reports, imaging reports (High resolution computerized tomography scan of chest, paranasal sinuses and brain (HRCT chest, CT PNS and CT brain)), treatment details, including antifungal drug therapy and surgical debridement, data on use of supplemental oxygen, mechanical ventilation and hospitalization outcomes. Mild COVID was defined as individuals who have various signs and symptoms of COVID-19 but who do not have shortness of breath, dyspnea, or abnormal chest imaging [62]. Moderate disease was defined as patients who show evidence of lower respiratory disease during clinical assessment or imaging and who have oxygen saturation (SpO₂) 90 to \leq 93% on room air. Severe COVID was defined as SpO₂ < 90% on room air, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO₂/FiO₂) < 300 mm Hg, respiratory frequency > 30 breaths/min or lung infiltrates >50% [62]. Critical COVID was defined as presentation with respiratory failure, septic shock, and/or multiple organ dysfunction. For all patients diagnosed with CAM, we also scrutinized inpatient case files until hospital discharge, death, or 1st September 2021—the date on which the database was locked—whichever happened first. Systemic complications developing in patients during hospital admission were also noted. All patients who died due to CAM during hospital admission were identified and a death audit to look for complications and cause of death was undertaken.

For patients who left the hospital against medical advice, we considered a worst-case scenario for mortality analysis and assumed the patients died. All patients who recovered, got discharged from NHRC and had outpatient follow-up at 15, 30 and 90 days after discharge were identified. Their outpatient follow-up visits were traced from electronic database to look for delayed complications.

Management of Mucormycosis at NHRC:

NHRC protocol for management of Mucormycosis has been developed after careful consideration of current global and national guidelines ^[63,64]. As per the protocol, early, radical, surgical debridement of affected site in addition to combination systemic antifungal therapy was utilized for treatment.

Surgical management:

Functional endoscopic paranasal sinus surgery (FESS) with debridement of necrosed and diseased sinus tissue and orbital decompression was the most common surgical procedure performed in patients with ROCM. All efforts were made to preserve the eye for as long as possible in view of role of eye to not only provide vision but also its removal causing significant psycho-social problems to patient. In patients with total blindness, proptosis, fixed pupil and eyeball, imaging evidence of orbital involvement by Mucor (globe/muscles/fat) and/or intracranial spread (superior orbital fissure/inferior orbital fissure involvement), surgical exenteration of the eye was performed [65]. Surgical exenteration of the eye with debridement of orbital cavity was performed in consultation with Department of Otorhinolaryngology and Ophthalmology. Partial or total maxillectomy was performed in patients with evidence of osteomyelitis of maxilla or alveolar arch. Neurosurgery was performed in case of intracranial spread of disease with involvement of skull base or formation of basi-frontal lobe brain abscess.

Medical management:

Combination therapy of Liposomal Amphotericin B (LAmB) and Oral Triazole (predominantly oral Posaconazole) was the most common medical treatment offered to all patients with CAM. LAmB was initiated at the dose of 5 mg/kg. The dose was increased to 10 mg/kg in case of intracranial spread ^[63,64]. In the scenario of shortage of LAmB due to surge in CAM cases or non affordability of patient, other formulations of Amphotericin B (Amphotericin B lipid complex (5 mg/kg), Amphotericin B lipid emulsion (5 mg/kg) and Amphotericin B de-

oxycholate (1 mg/kg)) were used for patients. The duration of Amphotericin B treatment was decided depending on the site of involvement (3 weeks for only paranasal sinus involvement, 4 weeks for orbital, lung and disseminated Mucormycosis and 6 weeks for Central nervous system (CNS) Mucormycosis). Oral Posaconazole (delayed release tablets, 300 mg twice a day on Day 1 and then 300 mg once a day) was started along with Amphotericin B treatment and continued after discharge from hospital for a period of 1 to 3 months depending on local control of disease and discretion of Infectious disease physician. In patients with concomitant chronic kidney disease, intravenous Posaconazole or Isavuconazole followed by step-down to oral therapy was treatment of choice. Serum Posaconazole levels were performed to guide dosage during oral therapy.

Outcomes:

- 304 Primary endpoint:
 - 1) Deaths in the cohort due to CAM.
 - Secondary outcomes:
 - 2) Number of patients who had a clinical and radiologic recovery and were discharged from hospital.
 - 3) Patients who required mechanical ventilation (noninvasive or invasive) and Intensive care unit (ICU) admission for CAM.
 - 4) Incidence of systemic complications (including long-term complications) in patients after starting Amphotericin B therapy.
 - The use of database for clinical research was approved by the institutional review board (IRB) of Noble hospital and Research Centre, Pune, India.

Statistical Methods:

Continuous variables were summarized using median and interquartile range (IQR), while categorical variables were summarized using frequency and percentages. Continuous variables were compared using a Mann Whitney U test. Categorical variables were compared using Chi-square test, Proportion test and Fishers' exact test. Baseline and time dependent risk factors significantly associated with death due to CAM were identified by Relative risk analysis. Baseline risk factors included for analysis were age (< 60 years or \geq 60 years), gender, severity of baseline COVID disease (CT severity index \geq 18 versus < 18), presence of orbital or central

nervous system (CNS) symptoms, presence of diabetic keto-acidosis, presence of intracranial spread (cerebral involvement) and baseline investigations like absolute lymphocyte count ($< 1000 \text{ versus} \ge 1000 \text{ cells/mm}^3$), C reactive protein ($\ge 50 \text{ versus} < 50 \text{ mg/L}$), D-dimer ($\ge 252 \text{ versus} < 252 \text{ mcg/mL}$) and Ferritin ($\ge 1000 \text{ versus} < 1000 \text{ mcg/L}$). Time dependent risk factors included duration of Amphotericin B therapy ($< 3 \text{ weeks versus} \ge 3 \text{ weeks}$) and development of systemic complications like acute kidney injury, hepatitis, anemia, thrombocytopenia, osteomyelitis and CNS complications (stroke or cerebritis). The p value $\le 0.05 \text{ was considered}$ as statistically significant. All data was analyzed by SPSS version 12.0.

Results:

During the period between 1st April 2020 to 1st August 2021, 59 patients were diagnosed with Mucormycosis at NHRC. Fifty-eight patients were diagnosed to have ROCM while 1 patient was diagnosed to have Renal (disseminated) mucormycosis. Median age of the cohort was 52 (IQR: 41, 61) years and it included 20.3 % (12/59) females. Seventeen (28.8 %) patients were > 60 years of age. Fifty-six (95 %) patients had pre-existing or newly diagnosed comorbidities. Diabetes mellitus (53/59, 89.8 %) was the most common co-morbidity seen in our cohort. Of these, 15 patients (28.3 %) were newly diagnosed with diabetes during hospital admission for COVID-19. Two patients were diagnosed to have impaired fasting glucose (Fasting blood glucose between 110 and 125 mg/dl). Preexisting co-morbidities observed in patients at admission are enumerated in Table 1. Three patients (5.1%) had no co-morbidities prior to developing CAM.

Clinically, 16 patients (27.1%) had mild COVID, 29 (49.2 %) had moderate COVID and 14 patients (23.7%) had severe or critical COVID disease prior to diagnosis of Mucormycosis. All 59 patients underwent High resolution CT (HRCT) imaging of chest (GE Optima, 128 slice CT scanner) during admission for COVID-19 and median CT severity index was 12 (IQR: 8,14.5). CT severity index [66] indicated mild disease (CT severity index: < 8) in 18.6 % (11/59), moderate disease (CT severity index: 8-14) in 56 % (33/59) and severe disease (CT severity index: 15-25) in 25.4 % (15/59) of patients. Treatments given during COVID-19 admission are enumerated in Table 2a and 2b. Remdesivir was prescribed to 67.8 % (40/59), intravenous and/or oral steroids were prescribed to 100 % and Immune-modulator therapy (Tocilizumab - 5, Barcitinib-2, Idofinib- 1, Infliximab- 2, Bevacizumab - 2 and Itolizumab - 1) was prescribed to

22 % (13/59) patients in our cohort. Methylprednisolone was the commonest prescribed steroid (54 patients, 91.5%, Table 2b). Most commonly prescribed dose of Methylprednisolone was 1-2 mg/kg/day in divided doses for 5 to 10 days ^[67]. Ten patients (16.9 %) were prescribed 2 different steroids during treatment course for COVID-19. 56 % (33/59) patients were prescribed steroids in the absence of hypoxia (irrational or unscientific steroid use). In 5 (5/54, 9.3%) patients, Methylprednisolone dose of more than 2 mg/kg/day was prescribed for treatment of severe COVID-19 (wrong or excess steroid dose). Eleven patients (18.6%) required ICU admission while 7 (11.9 %) needed noninvasive or invasive ventilation during hospital admission of COVID-19 infection. Thirteen patients (22%) had received COVID vaccination prior to admission (3 patients received 2 vaccine doses and 10 patients received single vaccine dose, Table 1). Five patients (8.5 %) were treated for COVID-19 while in home quarantine and did not require hospital admission. All 5 patients in home quarantine received steroids (irrational or unscientific steroid use) as a part for of their treatment regimen. Median duration of hospital admission for COVID-19 was 9 (IQR: 6, 14) days.

Median duration from first positive COVID-19 RT PCR test to diagnosis of Mucormycosis was 17 (IQR: 12, 22) days. Duration was less than 14 days for 22 (37.3 %, early CAM) patients while it was > 14 days for 37 (62.7 %, late CAM) patients. Median duration between hospital discharge for COVID-19 to re-admission for Mucormycosis was 7 (IQR: 2.5, 15.5) days. Twenty patients (33.9 %) were diagnosed to have Mucormycosis (suspected fungal sinusitis, ROCM) during admission for COVID-19. Twenty-seven (45.7 %) were re-admitted less than 14 days after hospital discharge for COVID-19 while 12 (20.4 %) were re-admitted after more than 14 days. Headache (43/58, 74.1 %), hemi-facial pain predominantly maxillary pain (42/58, 72.4 %) and facial swelling (33/58, 56.9 %) were the three commonest presenting symptoms of ROCM in our cohort (Table 3). Median duration of symptoms was 6 (IQR: 3, 8.5) days. Seven patients (11.9 %) had symptoms for more than 2 weeks prior to diagnosis of ROCM. Fifty-eight patients (99%) had rhinal (paranasal sinus) involvement, 33 (56%) had orbital (eyeball, extra-ocular muscles or orbital cavity) and 26 (44.1%) had cerebral involvement (infarcts, cavernous sinus involvement, dural enhancement, frontal lobe abscess, osteomyelitis and erosion of frontal bone, Table 3). Palatal involvement (palatal necrosis, black eschar or palatal osteomyelitis) was observed in 13 (22 %) patients. Median hemoglobin value at diagnosis

of Mucormycosis was 13.4 (IQR: 11.4, 14.5) mg/dl (Table 4). Median absolute neutrophil count (ANC) was 8100 (IQR: 5248, 11475) cells/mm³ and median absolute lymphocyte count (ALC) was 1350 (IQR: 1010, 1750) cells/mm³. Fourteen patients (24.6 %) had ALC < 1000 cells/mm³ while no patient had ANC < 1000 cells/mm³ at admission. Median CRP at admission was 84.7 (IQR: 41,167, 45 patients) mg/L, median D-dimer was 483.5 (IQR: 253.7,1201, 37 patients) mcg/mL, and median Ferritin value was 857.1 (IQR: 280.5, 1429, 32 patients) mcg/L. Thirteen patients (40.6 %) had serum Ferritin level > 1000 mcg/L at admission while 11 patients had D-dimer > 1000 mcg/mL. Median HbA1C level in our cohort was 9.3 (IQR: 8, 12). Ten patients (10/53, 18.9%) presented with diabetic ketoacidosis. Diagnosis of Mucormycosis was made by KOH/calcofluor white staining of nasal scrapings (25/59, 42.4%), culture (5/59, 8.5%) and histopathologic examination of excised tissue from paranasal sinuses (57/59, 96.6%). Mixed mould infection (mucormycosis and aspergillosis) was observed in 3 patients.

Aggressive surgical debridement of involved site and combination antifungal therapy was standard of care for all ROCM patients in our cohort. Empirical combination anti-fungal therapy was started after radiologic evidence of invasive sinusitis, pending confirmatory diagnosis by histopathology or culture. Various treatment modalities used in our cohort are mentioned in Table 5. Intravenous (IV) formulations of Amphotericin B (Liposomal, Lipid-complex, Lipid emulsion or Deoxycholate) were the mainstay of antifungal therapy and prescribed to 91.5% (54/59) patients. In view of shortage of Liposomal Amphotericin B in India during the second COVID-19 wave, patients ended up getting a combination of Amphotericin B formulations as per availability. Liposomal Amphotericin B was prescribed to 89.8 % (53/59) patients for a median duration of 15 (IQR: 11, 21) days. Amphotericin B de-oxycholate or Conventional Amphotericin B was prescribed to 45.8% (27/59) patients for a median duration of 4 (IQR: 3, 9) days. The median duration of Amphotericin B exposure to patients in our cohort was 21 (IQR: 14, 27) days. All patients were also prescribed concomitant oral triazole therapy (Posaconazole (58/59, 98.3%) or Isavuconazole (5/59, 8.5%)) during admission and after discharge till clinician was satisfied about local control of disease. Median duration for oral triazole therapy was 60 days. FESS with orbital decompression was performed on 94.9 % patients (56/59). Surgical exenteration of the eye with debridement of orbital cavity was performed in 13 (22 %) patients. Partial maxillectomy was performed in 9 (15.3 %) patients while Neurosurgery for frontal lobe

brain abscess drainage was performed in 5 (8.5 %) patients. Eight patients (13.6 %) required invasive mechanical ventilation while 18 (30.5 %) required ICU admission for Mucormycosis.

Complications during antifungal therapy and hospital admission are mentioned in Table 6. Fever with chills (78 %), Thrombophlebitis (59.3 %), Hypokalemia (88.1 %), Anemia (57.6 %) and Nephrotoxicity (50.8 %) were the most common complications observed during hospital admission. Central nervous system (CNS) complications (stroke/cerebritis/brain abscess) were seen in 25.4 % patients. There were 14 deaths (23.7 %) in our cohort during first hospital admission for Mucormycosis. On Relative risk analysis, CT severity score during COVID-19 admission ≥ 18 (p = 0.017), presence of symptoms like eye swelling (p = 0.002), loss of vision (p < 0.0001), ptosis (p = 0.005) and limb weakness (p = 0.001), presence of diabetic ketoacidosis (p = 0.011), cerebral involvement by Mucor (p = 0.0004) and development of CNS complications like stroke (p < 0.0001) during antifungal therapy were associated with increased risk of death (Table 7, Figure 1). Duration of Amphotericin B treatment of more than 21 days was associated with decreased risk of death (p = 0.002) on Relative risk analysis (Table 7). All patients who were discharged from hospital were followed up for a minimum period of 6 weeks to look for late complications. Three patients needed re-admission, 48, 54 and 37 days after first discharge in view of re-appearance of symptoms and/or imaging evidence of progression of disease to the CNS. All 3 patients needed repeat surgical debridement and additional Amphotericin B treatment. They were successfully discharged the second time. Two patients also needed readmission for osteomyelitis of maxilla and alveolar arch which needed partial maxillectomy and placement of dental prosthesis. One patient who had undergone exentration of eye was readmitted 90 days later for insertion of orbital prosthesis. One patient who had been treated for cerebral mucormycosis (bilateral complete vision loss and multiple cerebral infarcts) with 42 days of high dose Liposomal Amphotericin B and Posaconazole was readmitted with aspiration pneumonia 12 days later and died. Cause of death was respiratory failure due to aspiration pneumonia and acute respiratory distress syndrome (ARDS, Total deaths in cohort - 15, 25.4%).

Discussion:

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

We conducted a single-centre, retrospective cohort study of 59 patients with CAM who were admitted at NHRC in the last 15 months. 74.6% patients could be successfully discharged

after control of disease with combined surgical and medical approach. Mortality rate in our cohort at 6 weeks follow-up was 25.4 %.

Majority of the patients in our study were middle-aged (median age: 52□years), of which nearly two-thirds were male. It has been hypothesized that the effect of estrogen might be protective in systemic fungal infection, which could have led to lower incidence in females ^[68]. Case series on CAM by Sharma et al ^[46], described diabetes as a risk factor in 90% cases of which 52% had uncontrolled disease. A systematic review of 101 cases of CAM by Singh et al ^[58] also noted that more than 80% cases had either pre-existing or new onset hyperglycaemia as a risk factor. Our study has demonstrated similar findings in that 90 % of included patients were diabetic with almost 30% being newly diagnosed with DM at the time of admission for COVID-19. Of the 56 patients who had HbA1c value available, 50 had uncontrolled DM (HbA1c > 7%). Median HbA1c in our cohort was 9.3% while it was 9.6% in the study by Sen et al ^[55]. Tight control of blood sugar level among patients with Diabetes Mellitus/ COVID-19 co-infection could help in reducing incidence of ROCM.

Both the RECOVERY trial ^[17] and WHO COVID-19 ^[69] guidelines clearly recommend against usage of Corticosteroids in COVID-19 patients not requiring oxygen (absence of hypoxia). Despite that, indiscriminate use of steroids in mild COVID-19 continues in India. The underlying reasons include the sudden surge of cases during second COVID wave leading to panic among general practitioners, inadequate time for triaging patients in busy outpatient clinics, non evidence-based clinical practice, availability of over the counter steroids, shortage of hospital beds and inadequate monitoring of the patients taking steroids. The improper use of corticosteroids has been identified as an independent risk factor for CAM by the MucoCovi network ^[7]. In their retrospective analysis of 187 Indian CAM patients, they found that 78% (150/187) had received steroid therapy but only 33% patients had received steroids at appropriate dosages. In 33 % patients (50/150), steroids were not indicated while among 30% (45/150) patients steroids were indicated but were prescribed in inappropriately high dose ^[7]. In comparison, in our study, 56 % patients were prescribed steroids for non-hypoxemic, mild to moderate COVID illness (irrational steroid therapy) while in 8.5 % patients steroids were indicated but were prescribed in inappropriately high dose. Thus there is an urgent need to stop

prescription of steroids in non-hypoxemic COVID-19 patients and to limit the dose and duration of steroids in hypoxic patients.

In our cohort, majority of the patients were treated with a combination of surgical debridement (94%) and intravenous Amphotericin B therapy (91%). Mortality rate at 6 weeks follow-up was 25.4 % which is lower than what is reported by Pal et al [57] and Patel et al (MucoCovi network - 6 week mortality rate of 38.3 % and 12 week mortality of 45.7 %) [7]. Reasons for lower mortality in our cohort as compared to the MucoCovi network [7] could be relatively younger population (median age 52 years versus 56.9 years), lower prevalence of hypoxia during COVID-19 (44 % versus 56 %), lower pulmonary involvement due to Mucormycosis (0 % versus 8.6 %), increased use of combination antifungal therapy (91% versus 50%) and higher use of combined surgical and medical approach (91% versus 71%). However, presence of diabetic ketoacidosis (10.9 % versus 8.6 %) and prevalence of cerebral involvement due to Mucor (44 % versus 23 %) was higher in our cohort than the MucoCovi study ^[7]. Both the factors, presence of diabetic ketoacidosis (p = 0.011) and cerebral involvement with Mucor (p = 0.0004) were associated with higher risk of mortality on Relative risk analysis. In patients with cerebral involvement due to Mucor, mortality rate was 50% which is 5 times higher than among patients without cerebral involvement. On the other hand, duration of Amphotericin B therapy of more than 21 days was associated with statistically significant reduction in mortality (p = 0.002). Development of ROCM while the patient is still under active treatment for moderate or severe COVID-19 may pose significant challenges in the management – specifically termination of corticosteroids, and surgery under general anesthesia. This was reflected in the CT severity index > 18 (depicting severe COVID pneumonia) being a significant risk factor for increased risk of death due to CAM (p = 0.017). Patients with ROCM also remain at risk for delayed complications and may need re-admission with further surgical and anti-fungal treatment to resolve them.

Limitations:

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486 487

488

489

490

491

492

493

494

495

496

497

498

499

500

Our study has several limitations. First, this is not a randomized controlled trial, and therefore unmeasured confounding cannot be ruled out. Second, as for all retrospective studies, some individuals diagnosed with Mucormycosis may be unreported leading to measurement bias and underestimation of mortality due to CAM. Third, we collected data from a single centre in

India unlike other multicenter cohort studies ^[7, 52,54,55,57]. Fourth, an overwhelmed health care system, inadequate workforce and lack of exhaustive reporting due to surge of cases during second COVID wave could be responsible for underestimation of co-morbidities, presenting symptoms and complications amongst patients in our cohort. Fifth, inflammatory markers like Ferritin, CRP and D-dimer were not available for all patients in the cohort. Sixth, we did not look for environmental factors causing healthcare-associated mucormycosis like contaminated ventilation systems, air conditioners, and ongoing construction in our hospital. We did not estimate the burden of Mucormycetes spores in our hospital environment. We also didn't investigate the link between risk factors like use of industrial oxygen during the COVID pandemic, contaminated nebulizer fluids or inline humidifier tubing used in ventilator circuits and contaminated oxygen delivery systems with increased incidence of CAM in our cohort ^[10]. Seventh, other unexplored factors, including genetic predisposition were not identified.

Despite these limitations, this retrospective cohort study adds to the growing body of literature on epidemiology, management strategies, outcomes and long term complications due to COVID-19 associated Mucormycosis (CAM).

Conclusions:

COVID-19 associated Mucormycosis (CAM) is an uncommon, rapidly progressive, angio-invasive, opportunistic fungal infection which is fatal if left untreated. The most common form of CAM seen in our cohort was the Rhino-orbito-cerebral (ROCM) one. COVID-19 induced immune dysregulation, uncontrolled diabetes mellitus and indiscriminate use of steroids may be the risk factors associated with the sudden surge in Mucormycosis cases in India during the second wave. Clinicians should have a high index of suspicion for ROCM in patients recovering from COVID-19, especially among patients with new or previously diagnosed diabetes mellitus and clinical manifestations of headache, facial or orbital pain. Combination of surgical debridement and intravenous Amphotericin B therapy leads to clinical and radiologic improvement in majority of cases. Cerebral involvement by Mucor is associated with higher mortality.

Acknowledgements:

Manisha Ghate MD, PhD (National AIDS Research Institute (NARI), Pune, India) - edited the manuscript.

References:

531

541

542

543

544

545

546

547

548

549

550

551

552

553

- 1) Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA*. 2020. https://doi.org/10.1001/jama.2020.2648
- 2) World health organization (WHO): Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it.
- 3) World health organization (WHO) Coronavirus disease (COVID-19) dashboard.

 Available at: https://covid19.who.int.
 - 4) Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 2020 Dec 3; 71(9):2459-2468. doi: 10.1093/cid/ciaa530. PMID: 32358954; PMCID: PMC7197596.
 - 5) Song G, Liang G, Liu W. Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China. Mycopathologia. 2020 Aug; 185(4):599-606. doi: 10.1007/s11046-020-00462-9. Epub 2020 Jul 31. PMID: 32737747; PMCID: PMC7394275.
 - 6) Press release from Government of India at https://pib.gov.in/PressReleasePage.aspx?PRID=1728153 accessed July 21st, 2021.
 - 7) Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R et al; MucoCovi Network3. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India. Emerg Infect Dis. 2021 Jun 4; 27 (9). doi: 10.3201/eid2709.210934. Epub ahead of print. PMID: 34087089.
- 8) Chakrabarti A, Kaur H, Savio J, Rudramurthy SM, Patel A, Shastri P et al. Epidemiology and clinical outcomes of invasive mould infections in Indian intensive care units (FISF

- study). J Crit Care. 2019 Jun;51 :64-70. doi: 10.1016/j.jcrc.2019.02.005. Epub 2019 Feb 5. PMID: 30769292.
- 9) Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. J Fungi (Basel). 2019
 Mar 21; 5(1):26.
- 10) Narayanan S, Chua JV, Baddley JW. COVID-19 associated Mucormycosis (CAM): risk factors and mechanisms of disease. Clin Infect Dis. 2021 Aug 22:ciab726. doi: 10.1093/cid/ciab726. Epub ahead of print. PMID: 34420052.
- 564 11) García LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19.

 Front Immunol. 2020 Jun 16; 11: 1441. https://doi.org/10.3389/fimmu.2020.01441
- 12) Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in 566 567 COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct **Target** 2020 May 29: 568 Ther. 5(1):84. https://doi.org/10.1038/s41392-020-0191-1 569
- 13) IDF Diabetes ATLAS Ninth Edition. 2019. https://diabetesatlas.org/upload/resources/
 material/20200 302_133351_IDFAT LAS9e -final -web. pdf#page=42&zoom=auto.
 Accessed May 12, 2020.
- 573 14) Anjana RM, Deepa M, Pradeepa R, et al. Prevalence of diabetes and prediabetes in 15 574 states: results from the ICMR–INDIAB population-based cross-sectional study. *Lancet* 575 Diabetes Endocrinol.2017;5: 585-596.
- 15) Müller JA, Groß R, Conzelmann C, et al. SARS-CoV- 2 infects and replicates in cells of
 the human endocrine and exocrine pancreas. *Nat Metab.* 2021; 3: 149-165.
 https://doi.org/10.1038/s4225 5-021- 00347-1.
- 579 16) WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, 580 Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC et al. Association 581 Between Administration of Systemic Corticosteroids and Mortality Among Critically III 582 Patients With COVID-19: A Meta-analysis. *JAMA*. 2020 Oct 6; 324(13):1330-1341. 583 https://doi.org/10.1001/jama.2020.17023
- 584 17) RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L et al. Dexamethasone in Hospitalized Patients with Covid-19 Preliminary

586	Report. N Engl J Med. 2020 Jul 17: NEJMoa2021436.
587	https://doi.org/10.1056/NEJMoa2021436
588	18) Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet.
589	2003 Nov 29;362(9398):1828-38. doi: 10.1016/S0140-6736(03)14904-5. PMID:
590	14654323.
591	19) Rodriguez-Morales AJ, Sah R, Millan-Oñate J, Gonzalez A, Montenegro-Idrogo JJ,
592	Scherger S et al. COVID-19 associated mucormycosis: the urgent need to reconsider the
593	indiscriminate use of immunosuppressive drugs. Ther Adv Infect Dis. 2021 Jun 18;8:
594	20499361211027065. doi: 10.1177/20499361211027065. PMID: 34211710; PMCID:
595	PMC8216396.
596	20) Actemra (tocilizumab) Prescribing information. South San Francisco, CA: Genentech,
597	Inc; 2019.
598	21) Ibrahim AS, Spellberg B, Edwards J. Iron acquisition: a novel perspective on
599	mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008; 21: 620-625.
600	https://doi.org/10.1097/QCO.0b013 e3283 165fd1
601	22) Perricone C, Bartoloni E, Bursi R, et al. COVID-19 as part of the hyperferritinemic
602	syndromes: the role of iron depletion therapy. <i>Immunol Res.</i> 2020; 68: 213-224.
603	https://doi.org/10.1007/s1202 6-020-09145-5.
604	23) Pasero D, Sanna S, Liperi C, Piredda D, Branca GP, Casadio L, Simeo R, Buselli A,
605	Rizzo D, Bussu F, Rubino S, Terragni P. A challenging complication following SARS-
606	CoV-2 infection: a case of pulmonary mucormycosis. Infection. 2020 Dec 17:1-6. doi:
607	10.1007/s15010-020-01561-x. Epub ahead of print. PMID: 33331988; PMCID:
608	PMC7745708.
609	24) Monte Junior ESD, Santos M, Ribeiro IB, et al. Rare and fatal gastrointestinal
610	mucormycosis (Zygomycosis) in a COVID-19 patient: a case report. Clin Endosc 2020;

25) Deutsch P.G., Whittaker J., Prasad S. Invasive and non-invasive fungal rhinosinusitis—a review and update of the evidence. *Medicina*. 2019;55: 1–14.

53: 746–749.

- 26) Brunet K and Rammaert B. Mucormycosis treatment: recommendations, latest advances, and perspectives. J Mycol Med 2020; 30: 101007.
- 27) Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, Puri GD, Chakrabarti
 A, Agarwal R. Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case
 Report and Systematic Review of Literature. Mycopathologia. 2021 May;186(2):289298. doi: 10.1007/s11046-021-00528-2. Epub 2021 Feb 5. PMID: 33544266; PMCID:
 PMC7862973.
- 28) Baskar HC, Chandran A, Reddy CS, Singh S. Rhino-orbital mucormycosis in a COVID 19 patient. BMJ Case Rep. 2021 Jun 24;14(6):e244232. doi: 10.1136/bcr-2021-244232.
 PMID: 34167998; PMCID: PMC8230977.
- 29) Rao R, Shetty AP, Nagesh CP. Orbital infarction syndrome secondary to rhino-orbital mucormycosis in a case of COVID-19: Clinico-radiological features. Indian J Ophthalmol. 2021 Jun;69(6):1627-1630. doi: 10.4103/ijo.IJO_1053_21. PMID: 34011758.
- 628 30) Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med 2021; 42: 264. e5–264.e8.
- 31) Placik DA, Taylor WL and Wnuk NM. Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia. Radiol Case Rep 2020; 15: 2378–2381.
- 32) Kanwar A, Jordan A, Olewiler S, et al. A fatal case of Rhizopus azygosporus pneumonia
 following COVID-19. J Fungi (Basel) 2021; 7: 174.
- 33) Dallalzadeh LO, Ozzello DJ, Liu CY, et al. Secondary infection with rhino-orbital
 cerebral mucormycosis associated with COVID-19. Orbit. Epub ahead of print 23 March
 2021. DOI: 10.1080/01676830.2021.1903044.
- 34) Johnson AK, Ghazarian Z, Cendrowski KD, et al. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. Med Mycol Case Rep 2021; 32: 64–67.
- 35) Zurl C, Hoenigl M, Schulz E, et al. Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically ill COVID-19 patient with underlying hematological malignancy. J Fungi (Basel) 2021; 7: 88.

- 36) Khatri A, Chang KM, Berlinrut I, et al. Mucormycosis after coronavirus disease 2019
 infection in a heart transplant recipient case report and review of literature. J Mycol
 Med 2021; 31: 101125.
- 37) Waizel-Haiat S, Guerrero-Paz JA, Sanchez-Hurtado L, Calleja-Alarcon S, Romero-Gutierrez L. A Case of Fatal Rhino-Orbital Mucormycosis Associated With New Onset
 Diabetic Ketoacidosis and COVID-19. Cureus. 2021 Feb 5;13(2):e13163. doi:
 10.7759/cureus.13163. PMID: 33575155; PMCID: PMC7870113.
- 650 38) Bellanger AP, Navellou JC, Lepiller Q, et al. Mixed mold infection with Aspergillus 651 fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome 652 Coronavirus 2 (SARSCoV-2) patient. Infect Dis Now. Epub ahead of print 27 January 653 2021. DOI: 10.1016/j. idnow.2021.01.010.

655

656

657

658

659

660

661

662

- 39) Ahmadikia K, Hashemi SJ, Khodavaisy S, et al. The double-edged sword of systemic corticosteroid therapy in viral pneumonia: a case report and comparative review of influenza associated mucormycosis versus COVID-19 associated mucormycosis. Mycoses. Epub ahead of print 16 February 2021. DOI: 10.1111/ myc.13256.
 - 40) Karimi-Galougahi M, Arastou S and Haseli S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol. Epub ahead of print 13 March 2021. DOI: 10.1002/alr.22785.
- 41) Veisi A, Bagheri A, Eshaghi M, et al. Rhinoorbital mucormycosis during steroid therapy in COVID-19 patients: a case report. Eur J Ophthalmol. Epub ahead of print 10 April 2021. DOI: 10.1177/11206721211009450.
- 42) Meshram HS, Kute VB, Chauhan S, Desai S. Mucormycosis in post-COVID-19 renal transplant patients: A lethal complication in follow-up. Transpl Infect Dis. 2021. June
 3:e13663. https://doi.org/10.1111/tid.13663 10.1111/tid.13663 PMid: ;PMCiD: . DOI PubMed
- 668 43) Mehta S and Pandey A. Rhino-orbital mucormycosis associated with COVID-19. 669 Cureus 2020; 12: e10726.
- 44) Sen M, Lahane S, Lahane TP, et al. Mucor in a viral land: a tale of two pathogens.
 Indian J Ophthalmol 2021; 69: 244–252.

- 45) Sarkar S, Gokhale T, Choudhury SS, et al. COVID-19 and orbital mucormycosis. Indian
 J Ophthalmol 2021; 69: 1002–1004.
- 46) Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. Epub ahead of print 8 April 2021. DOI: 10.1017/S0022215121000992.
- 47) Saldanha M, Reddy R, Vincent MJ. Paranasal mucormycosis in COVID-19 patient.
 Indian J Otolaryngol Head Neck Surg. Epub ahead of print 22 April 2021. doi:
 10.1007/s12070-021- 02574-0.
- 48) Revannavar SM, Supriya PS, Samaga L, et al. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ Case Rep 2021; 14: e241663.
- 49) Maini A, Tomar G, Khanna D, et al. Sino-orbital mucormycosis in a COVID-19 patient: a case report. Int J Surg Case Rep 2021; 82: 105957.
- 50) Krishna V, Morjaria J, Jalandari R, Omar F, Kaul S. Autoptic identification of disseminated mucormycosis in a young male presenting with cerebrovascular event, multi-organ dysfunction and COVID-19 infection. IDCases. 2021;25:e01172. doi: 10.1016/j.idcr.2021.e01172. Epub 2021 May 28. PMID: 34075329; PMCID: PMC8161734.
- 51) Ravani SA, Agrawal GA, Leuva PA, et al. Rise of the phoenix: mucormycosis in COVID-19 times. Indian J Ophthalmol 2021; 69: 1563–1568
- 52) Selarka L, Sharma S, Saini D, Sharma S, Batra A, Waghmare VT et al. Mucormycosis
 and COVID-19: An epidemic within a pandemic in India. Mycoses. 2021 Jul 13. doi:
 10.1111/myc.13353. Epub ahead of print. PMID: 34255907.
- 53) Moorthy A, Gaikwad R, Krishna S, et al. SARS-CoV-2, Uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. Epub ahead of print 6 March 2021. DOI: 10.1007/s12663-021-01532-1.
- 54) Pakdel F, Ahmadikia K, Salehi M, Tabari A, Jafari R, Mehrparvar G, Rezaie Y, Rajaeih
 S, Alijani N, Barac A, Abdollahi A, Khodavaisy S. Mucormycosis in patients with
 COVID-19: A cross-sectional descriptive multicentre study from Iran. Mycoses. 2021

- Jun 7:10.1111/myc.13334. doi: 10.1111/myc.13334. Epub ahead of print. PMID:
 34096653; PMCID: PMC8242414.
- 55) Sen M, Honavar SG, Bansal R, Sengupta S, Rao R, Kim U, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. *Indian J Ophthalmol*. 2021;69 (7):1670-1692. doi:10.4103/ijo.IJO_1565_21.
- 56) Ramaswami A, Sahu AK, Kumar A, Suresh S, Nair A, Gupta D et al. COVID-19 associated Mucormycosis Presenting to the Emergency Department An Observational Study of 70 Patients. QJM. 2021 Jul 12: hcab190. doi: 10.1093/qjmed/hcab190. Epub ahead of print. PMID: 34254132.
- 57) Pal R, Singh B, Bhadada SK, Banerjee M, Bhogal RS, Hage N et al. COVID-19associated mucormycosis: An updated systematic review of literature. Mycoses. 2021 Jun 16. doi: 10.1111/myc.13338. Epub ahead of print. PMID: 34133798.
- 58) Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021 May 21;15 (4):102146. doi: 10.1016/j.dsx.2021.05.019. Epub ahead of print. PMID: 34192610; PMCID: PMC8137376.

721

722

723

724

725

726

727

728

- 59) Mishra Y, Prashar M, Sharma D, Akash Kumar VP, Tilak TVSVGK. Diabetes, COVID 19 and mucormycosis: Clinical spectrum and outcome in a tertiary care medical center in Western India. Diabetes Metab Syndr. 2021 Jul 3;15 (4):102196. doi: 10.1016/j.dsx.2021.102196. Epub ahead of print. PMID: 34246939; PMCID: PMC8253699.
- 60) Kumari A, Rao NP, Patnaik U, Malik V, Tevatia MS, Thakur S et al. Management outcomes of mucormycosis in COVID-19 patients: A preliminary report from a tertiary care hospital. Med J Armed Forces India. 2021 Jul;77: S289-S295. doi: 10.1016/j.mjafi.2021.06.009. Epub 2021 Jul 26. PMID: 34334896; PMCID: PMC8313063.
- 730 61) Dubey S, Mukherjee D, Sarkar P, Mukhopadhyay P, Barman D, Bandopadhyay M et al.

 COVID-19 associated rhino-orbital-cerebral mucormycosis: An observational study

732	from Eastern India, with special emphasis on neurological spectrum. Diabetes Metab
733	Syndr. 2021 Sep 1:102267. doi: 10.1016/j.dsx.2021.102267. Epub ahead of print.
734	PMCID: PMC8407938.
735	62) CLINICAL MANAGEMENT PROTOCOL: COVID-19. Government of India Ministry
736	of Health and Family Welfare Directorate General of Health Services (EMR Division).
737	Version 5. Published May 2021. Available at:
738	https://www.mohfw.gov.in/pdf/UpdatedClinicalManagementProtocolforCOVID19dated0
739	<u>3072020.pdf</u> .
740	63) Guideline for management of Mucormycosis in Covid – 19 patients. Government of
741	India Ministry of Health and Family Welfare Directorate General of Health Services
742	(EMR Division). Available at:
743	https://dghs.gov.in/WriteReadData/News/202105171119301555988Mucormycosismana
744	gementinCovid-19.pdf
745	64) Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis
746	and management of mucormycosis: an initiative of the European Confederation of
747	Medical Mycology in cooperation with the Mycoses Study Group Education and
748	Research Consortium. Lancet Infect Dis 2019; 19: e405-e421.
749	65) Shah K, Dave V, Bradoo R, Shinde C, Prathibha M. Orbital Exenteration in Rhino-
750	Orbito-Cerebral Mucormycosis: A Prospective Analytical Study with Scoring
751	System. Indian J Otolaryngol Head Neck Surg. 2019; 71 (2):259-265.
752	doi:10.1007/s12070-018-1293-8.
753	66) Francone M, Iafrate F, Masci GM, Coco S, Cilia F, Manganaro Let al. Chest CT score in
754	COVID-19 patients: correlation with disease severity and short-term prognosis. Eur
755	Radiol. 2020 Dec; 30(12): 6808-6817. https://doi.org/10.1007/s00330-020-07033-y.
756	67) AIIMS/ICMR-COVID-19 National Task force/Joint monitoring group (Dte GHS).
757	Ministry of health and family welfare, Government of India. Clinical guidance for
758	management of adult COVID-19 patients. Published 17th May 2021. Available at:
759	https://covid.aiims.edu/clinical-guidance-for-management-of-adult-covid-19-patients/

68) Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RLet al.

Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect

760

762 763	Dis. 2005 Sep 1; 41(5):634-53. doi: 10.1086/432579. Epub 2005 Jul 29. PMID: 16080086.
764	69) World health organization (WHO): COVID-19 Clinical management: living guidance.
765	Accessed 1 st September 2021. Available at:
766	https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1
700	https://www.who.mu/publications/1/html/w110-2017-html/v-chinicat-2021-1
767	
768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 797 798 799 800 801 802 803 804	
805 806	
807	

Table 1: Epidemiology of COVID-19 admission in Mucormycosis patients

Baseline characteristics	Total	Discharged	Death	p-value
	(N=59)	(n=44)	(n=15)	
	n (%)	n (%)	n (%)	
Age (Years)				0.077
≤ 60 years	42 (71.2)	34 (77.3)	8 (53.3)	
> 60 years	17 (28.8)	10 (22.7)	7 (46.7)	
Median (IQR)	52 (41, 61)	50 (40, 58)	57 (42, 65)	0.136
Gender				0.481
Male	47 (79.7)	36 (81.8)	11 (73.3)	
Female	12 (20.3)	8 (18.2)	4 (26.7)	
Co-morbidities				
Diabetes Mellitus				0.216
Non-diabetic	6 (10.2)	5 (11.4)	1 (6.7)	
Known Diabetes Mellitus	36 (61.0)	24 (54.5)	12 (80.0)	
Newly diagnosed DM/ IFG	17 (28.8)	15 (34.1)	2 (13.3)	
Hypertension	24 (40.7)	17 (38.6)	7 (46.7)	0.585
Chronic kidney disease	9 (15.3)	6 (13.6)	3 (20.0)	0.680
Ischemic Heart Disease	7 (11.9)	4 (9.1)	3 (20.0)	0.355
Chronic liver disease	2 (3.4)	0 (0.0)	2 (13.3)	0.061
Stroke	1 (1.7)	0 (0.0)	1 (6.7)	0.254
HIV/ Hepatitis B infection	1 (1.7)	1 (2.3)	0 (0.0)	>0.999
Obesity	2 (3.4)	1 (2.3)	1 (6.7)	0.447
Hypo/hyperthyroidism	3 (5.1)	2 (4.5)	1 (6.7)	>0.999
Severity of COVID-19				0.223
Mild	16 (27.1)	12 (27.3)	4 (26.7)	
Moderate	29 (49.2)	24 (54.5)	5 (33.3)	
Severe	14 (23.7)	8 (18.2)	6 (40.0)	
HRCT chest COVID severity score	, ,	, ,	, ,	0.047
< 18	55 (93.2)	43 (97.7)	12 (80.0)	
≥ 18	4 (6.8)	1 (2.3)	3 (20.0)	
Median (IQR)	12 (8, 15)	12 (8, 14)	14 (8, 17)	0.152
COVID-19 admission Median(IQR)	.,,,	.,,,	. , ,	
Duration of hospitalization (days)	9 (6, 14)	8 (6, 13.5)	10 (7, 15)	0.149
Duration of ICU stay (days)	0 (0, 10)	0 (0, 0)	0 (0, 10)	0.303
Duration of ventilation (days)	0 (0, 10)	0 (0, 0)	0 (0, 10)	0.046
COVID-19 vaccine status	. , ,	. , ,		0.826
No vaccination	46 (78.0)	34 (77.3)	12 (80.0)	
AstraZeneca - 1 dose	9 (15.3)	7 (15.9)	2 (13.3)	
AstraZeneca - 2 doses	2 (3.4)	1 (2.3)	1 (6.7)	
Covaxin (Bharat Biotech) - 1 dose	1 (1.7)	1 (2.3)	0 (0.0)	
Covaxin (Bharat Biotech)- 2 dose	1 (1.7)	1 (2.3)	0 (0.0)	

DM- Diabetes mellitus; IFG- Impaired fasting glucose; HRCT- High resolution computerized tomography; HIV- Human immunodeficiency virus

Table 2a: Drugs administered during COVID-19 treatment

Concomitant drugs	Total	Discharged	Death	p-value
	(N=59)	(n=44)	(n=15)	
	n (%)	n (%)	n (%)	
Meropenem	18 (30.5)	13 (29.5)	5 (33.3)	0.783
Teicoplanin	12 (20.3)	7 (15.9)	5 (33.3)	0.148
Clindamycin	0 (0.0)	0 (0.0)	0 (0.0)	
Doxycycline	25 (42.4)	19 (43.2)	6 (40.0)	0.829
Ivermectin	16 (27.1)	13 (29.5)	3 (20.0)	0.473
Piperacillin-Tazobactam	34 (57.6)	24 (54.5)	10 (66.7)	0.412
Polymyxin	2 (3.4)	0 (0.0)	2 (13.3)	0.061
Fluconazole	12 (20.3)	7 (15.9)	5 (33.3)	0.148
Caspofungin	2 (3.4)	0 (0.0)	2 (13.3)	0.061
Favipravir	35 (59.3)	25 (56.8)	10 (66.7)	0.503
Remdesivir	40 (67.8)	29 (65.9)	11 (73.3)	0.595
Hydroxychloroquine (HCQ)	0 (0.0)	0 (0.0)	0 (0.0)	
Azithromycin	4 (6.8)	4 (9.1)	0 (0.0)	0.564
Lopinavir/ritonavir	0 (0.0)	0 (0.0)	0 (0.0)	
Famotidine	0 (0.0)	0 (0.0)	0 (0.0)	
Enoxaparin	52 (88.1)	37 (84.1)	15 (100)	0.174
Immunomodulator therapy				
Not given	46 (78)	36 (81.8)	10 (66.7)	
Itolizumab	1 (1.7)	1 (2.3)	0 (0.0)	
Barcitinib	2 (3.4)	2 (4.5)	0 (0.0)	
Bevacizumab	2 (3.4)	2 (4.5)	0 (0.0)	
Bevacizumab+Infliximab	1 (1.7)	1 (2.3)	0 (0.0)	
Idofinib	1 (1.7)	1 (2.3)	0 (0.0)	
Infliximab	1 (1.7)	0 (0.0)	1 (6.7)	
Tocilizumab	5 (8.5)	1 (2.3)	4 (26.7)	
Convalescent Plasma	4 (6.8)	3 (6.8)	1 (6.7)	>0.999
Pirfenidone	12 (20.3)	6 (13.6)	6 (40.0)	0.028
Nintedanib	10 (16.9)	5 (11.4)	5 (33.3)	0.050
Dialysis	1 (1.7)	0 (0.0)	1 (6.7)	0.254
Noradrenaline	3 (5.1)	0 (0.0)	3 (20.0)	0.014
Vasopressin	1 (1.7)	0 (0.0)	1 (6.7)	0.254

Table 2b: Steroids and Supplemental Oxygen used during COVID-19 treatment

Steroids/Oxygen use in	Total	Discharged	Death	p-value	
COVID-19 treatment	(N=59)	(n=44)	(n=15)		
	n (%)	n (%)	n (%)		
Steroids given for treating COVID-19					
Methylprednisolone	54 (91.5)	40 (90.9)	14 (93.3)	>0.999	
Dexamethasone	4 (6.8)	4 (9.1)	0 (0.0)	0.564	
Oral Prednisolone	10 (16.9)	8 (18.2)	2 (13.3)	>0.999	
Oral Deflazacort	1 (1.7)	1 (2.3)	0 (0.0)	>0.999	
Oxygen given during treatment of COVID-	19				
Nasal oxygen by prongs	5 (8.5)	5 (11.4)	0 (0.0)	0.315	
Nasal oxygen by face mask	1 (1.7)	0 (0.0)	1 (6.7)	0.254	
Nasal oxygen by NRBM	28 (47.5)	21 (47.7)	7 (46.7)	0.943	
NRBM (days) Median (IQR)	7 (4, 10)	5 (4, 10)	7 (7, 10)	0.369	
HFNO	2 (3.4)	1 (2.3)	1 (6.7)	0.447	
HFNO (days) Median (IQR)	14 (10, 17)	17 (17, 17)	10 (10, 10)	0.317	
NIV	7 (11.9)	3 (6.8)	4 (26.7)	0.062	
NIV (days) Median (IQR)	8 (3, 15)	3 (3, 15)	9 (5, 14)	0.721	
Invasive mechanical ventilation (IMV)	3 (5.1)	0 (0.0)	3 (20.0)	0.014	
IMV (days) Median (IQR)	2 (1, 4)	0 (0, 0)	2 (1, 4)		

NRBM- Non re-breathing mask; IQR- Inter-quartile range; HFNO-High flow nasal oxygen; NIV- Non-invasive ventilation; IMV- Invasive mechanical ventilation

Table 3: Baseline characteristics of patients of Mucormycosis

Mucormycosis	Total	Discharged	Death	p-value
	n (%)	n (%)	n (%)	
Total patients	59	44 (74.6)	15 (25.4)	0.0002
Type of Mucormycosis				< 0.0001
Rhinal involvement only	24 (40.7)	24 (54.5)	0 (0.0)	
Rhinal + Orbital involvement	8 (13.6)	7 (15.9)	1 (6.7)	
Rhinal + Orbital + Cerebral	25 (42.4)	13 (29.5)	12 (80.0)	
Rhinal + Cerebral	1 (1.7)	0 (0.0)	1 (6.7)	
Renal	1 (1.7)	0 (0.0)	1 (6.7)	
Symptoms of Mucormycosis				
Facial pain	42 (71.2)	32 (72.7)	10 (66.7)	0.654
Facial swelling	33 (55.9)	22 (50.0)	11 (73.3)	0.142
Headache	43 (72.9)	32 (72.7)	11 (73.3)	>0.999
Eye swelling	33 (55.9)	20 (45.5)	13 (86.7)	0.007
Eye pain	29 (49.2)	17 (38.6)	12 (80.0)	0.007
Loss of vision	21 (35.6)	9 (20.5)	12 (80.0)	< 0.0001
Ptosis	21 (35.6)	11 (25.0)	10 (66.7)	0.004
Deviation of angle of mouth	5 (8.5)	3 (6.8)	2 (13.3)	0.593
Nasal discharge	15 (25.4)	13 (29.5)	2 (13.3)	0.310
Limb weakness	5 (8.5)	1 (2.3)	4 (26.7)	0.013
Toothache	27 (45.8)	24 (54.5)	3 (20.0)	0.034
Duration of symptoms (days) Median (IQR)	6 (3, 9)	6 (3, 10)	5 (3, 8)	0.488
Duration between 1st positive COVID-19 test and Mucormycosis diagnosis				0.751
< 7 days	2 (3.4)	2 (4.5)	0 (0.0)	
7-14 days	20 (33.9)	14 (31.8)	6 (40.0)	
15-28 days	28 (47.5)	20 (45.5)	8 (53.3)	
> 28 days	9 (15.3)	8 (18.2)	1 (6.7)	
Median (IQR)	17 (12, 22)	17 (13, 23)	17 (10, 21)	0.676

IQR- Interquartile range

Table 4: Baseline investigations during admission for Mucormycosis

Baseline characteristics	Total (N=59) n (%)	Discharged (n=44) n (%)	Death (n=15) n (%)	p-value
Laboratory investigations	H (70)	n (70)	H (70)	
Hemoglobin (g/dL)	13.4 (11.4, 14.5)	13.75 (12.05, 14.5)	12.5 (10.9, 13.9)	0.169
WBC (per microliter)	10400 (7000, 14400) 8100	10150 (7000, 13500) 7902	11900 (7000, 15400) 9559	0.568
Absolute Neutrophil count (ANC)	(5248, 11475)	(5214, 11260)	(5250, 13490)	0.447
Platelet count	227000 (178000, 308000)	231000 (189000, 308500)	198000 (160000, 308000)	0.186
Total Bilirubin (mg/dL)	1.035 (0.83, 1.36)	1.06 (0.85, 1.335)	0.905 (0.7, 1.41)	0.369
Direct Bilirubin conjugated (mg/dL)	0.315 (0.26, 0.46)	0.325 (0.26, 0.46)	0.295 (0.24, 0.6)	0.601
SGOT (units/L)	31 (18, 50)	28 (18, 40)	45 (32, 53)	0.054
SGPT (units/L)	35 (23, 52)	35 (22, 45)	47.5 (33, 99)	0.071
Blood urea level (mg/dL)	32 (22, 54)	28 (20.5, 49)	41 (27, 92)	0.030
Serum Creatinine (mg/dL)	1.1 (0.96, 1.27)	1.085 (0.96, 1.205)	1.12 (1.02, 1.61)	0.261
Potassium (mmol/L)	4 (3.5, 4.5)	4 (3.5, 4.4)	3.9 (3.2, 4.5)	0.656
Absolute Lymphocyte count (ALC, cells/mm3)				
< 1000	14 (24.6)	8 (18.2)	6 (46.2)	
≥ 1000	43 (75.4)	36 (81.8)	7 (53.8)	
Median (IQR)	1350 (1010, 1750)	1407.5 (1185, 1996.5)	1045 (595, 1308)	0.008
Procalcitonin (ng/mL)				
< 0.05	1 (2.5)	0 (0)	1 (9.1)	
0.05-2.0	28 (70)	22 (75.9)	6 (54.5)	
> 2.0	11 (27.5)	7 (24.1)	4 (36.4)	
Median (IQR)	0.38	0.392	0.341	0.797
Constant Destain (see II)	(0.2085, 2.735)	(0.207, 1.56)	(0.212, 3.81)	
C-reactive Protein (mg/L)	2 (4.7)	2 (6 2)	0 (0)	
0-6	2 (4.7)	2 (6.3)	0 (0)	
7-49	9 (20.9)	8 (25) 22 (68.8)	1 (9.1)	
≥ 50	32 (74.4)	` '	10 (90.9)	
Median (IQR)	84.7 (41, 167)	74.25 (39, 138.75)	173.735 (64.3, 207.5)	0.032
Ferritin (mcg/L)	(11, 107)	(3), 130.73)	(01.3, 207.5)	
15-150	3 (9.4)	3 (12.5)	0 (0)	
151-1000	16 (50)	13 (54.2)	3 (37.5)	
> 1000	13 (40.6)	8 (33.3)	5 (62.5)	
Median (IQR)	857.1 (280.5, 1429)	677.25 (262.55, 1108)	1346.5 (720.55, 1817.5)	0.089
D-Dimer (mcg/mL)	•	•	•	
< 252	9 (24.3)	7 (25.9)	2 (20)	
253-1000	17 (45.9)	13 (48.1)	4 (40)	
> 1000	11 (29.7)	7 (25.9)	4 (40)	
Median (IQR)	483.5 (253.73, 1201.00)	427.1 (237.08, 1071.71)	566.9 (255.48, 20)	0.321

WBC- White blood cell; IQR- Interquartile range; SGPT- Serum glutamate pyruvate transaminase;
 SGOT- Serum glutamate oxaloacetate transaminase.

Table 5: Treatment regimens used in Mucormycosis

Treatment regimen for Mucormycosis	Total	Discharged	Death	p-value
,	(N=59)	(n=44)	(n=15)	
	n (%)	n (%)	n (%)	
Drugs administered				
Liposomal Amphotericin B	53 (89.8)	42 (95.5)	11 (73.3)	0.032
Amphotericin B lipid complex/emulsion	17 (28.8)	17 (38.6)	0 (0.0)	0.003
Amphotericin B de-oxycholate	27 (45.8)	22 (50)	5 (33.3)	0.263
Total Amphotericin days				0.015
Not given	5 (8.5)	1 (2.3)	4 (26.7)	
\leq 21 days	30 (50.8)	20 (45.5)	10 (66.7)	
> 21 days	24 (40.7)	23 (52.3)	1 (6.7)	
Median (IQR)	21 (14, 27)	22 (15, 28)	10 (6, 21)	0.004
Posaconazole	58 (98.3)	44 (100)	14 (93.3)	0.254
Isavuconazole	5 (8.5)	5 (11.4)	0 (0.0)	0.315
Antibiotics given	55 (93.2)	40 (90.9)	15 (100.0)	0.564
Name of antibiotics				
Amoxicillin-Clavulanate	8 (13.6)	8 (18.2)	0 (0.0)	
Cefpodoxime	1 (1.7)	1 (2.3)	0 (0.0)	
Colistin	1 (1.7)	0 (0.0)	1 (6.7)	
Ceftriaxone-disodium edetate-sulbactam	2 (3.4)	2 (4.5)	0 (0.0)	
Cefoperazone-Sulbactum	1 (1.7)	1 (2.3)	0 (0.0)	
Meropenem	28 (47.5)	15 (34.0)	13 (86.7)	
Ceftriaxone	3 (5.1)	3 (6.8)	0 (0.0)	
Cefuroxime	1 (1.7)	1 (2.3)	0 (0.0)	
Piperacillin-Tazobactam	10 (16.9)	9 (20.5)	1 (6.7)	
Surgical procedures				
FESS	56 (94.9)	42(95.4)	14(93.3)	0.781
Orbital decompression	10 (16.9)	10 (22.7)	0 (0.0)	0.052
Palatal clearance	1 (1.7)	1 (2.3)	0 (0.0)	>0.999
Exenteration	13 (22)	6 (13.6)	7 (46.7)	0.008
Maxillectomy	9 (15.3)	9 (20.5)	0 (0.0)	0.095
Neurosurgery	5 (8.5)	3 (6.8)	2 (13.3)	0.593
Oxygenation and Ventilation data	1 (1.7)	0 (0 0)	1 (6.7)	0.254
Nasal oxygen by prongs	1 (1.7)	0 (0.0)	1 (6.7)	0.254
Nasal oxygen by face mask	0 (0.0)	0 (0.0)	0 (0.0)	0.000
Nasal oxygen by NRBM	5 (8.5)	4 (9.1)	1 (6.7)	>0.999
NRBM (days) Median (IQR)	13 (12, 14)	13 (12, 14)	ND	
HFNO	0 (0.0)	0 (0.0)	0 (0.0)	0.044
NIV	2 (3.4)	0 (0.0)	2 (13.3)	0.061
NIV (days) Median (IQR)	2 (1, 2)	0 (0, 0)	2 (1, 2)	0.015
Invasive mechanical ventilation (IMV)	8 (13.6)	1 (2.3)	7 (46.7)	<0.0001
IMV (days) Median (IQR)	3 (2, 4)	3 (3, 3)	3 (2, 4)	< 0.0001

ICU admissions

EECC Emptional and accoming					_
ICU stay (days) Median (IQR)	3 (3, 6)	3 (2, 7)	4 (3, 5)	< 0.0001	
Required ICU	18 (30.5)	8 (18.2)	10 (66.7)	< 0.0001	
D ICH	19 (20 5)	0 (10 2)	10 (((7)		.0.0001

FESS – Functional endoscopic sinus surgery; NRBM – Non re-breathing mask; IQR- Interquartile range; HFNO- High flow nasal oxygen; NIV- Non-invasive ventilation; IMV – Invasive mechanical ventilation.

Table 6: Complications in Mucormycosis patients during antifungal therapy

Complications in	Total	Discharged	Death	p-value	
Mucormycosis	(N=59)	(n=44)	(n=15)		
	n (%)	n (%)	n (%)		
Complications					
Acute kidney injury	30 (50.8)	22 (50)	8 (53.3)	0.824	
Hypokalemia	52 (88.1)	40 (90.9)	12 (80.0)	0.355	
Hepatitis	20 (33.9)	12 (27.3)	8 (53.3)	0.066	
Fever	46 (78.0)	35 (79.5)	11 (73.3)	0.721	
Chills	45 (76.3)	34 (77.3)	11 (73.3)	0.757	
Loose motions	14 (23.7)	11 (25.0)	3 (20.0)	>0.999	
Vomiting	21 (35.6)	15 (34.1)	6 (40.0)	0.680	
Loss of appetite	46 (78.0)	35 (79.5)	11 (73.3)	0.721	
Abdominal pain	9 (15.3)	5 (11.4)	4 (26.7)	0.213	
Abdominal Distension	2 (3.4)	1 (2.3)	1 (6.7)	0.447	
Thrombophlebitis	35 (59.3)	29 (65.9)	6 (40.0)	0.078	
Stomatitis	20 (33.9)	15 (34.1)	5 (33.3)	0.957	
Pedal edema	14 (23.7)	9 (20.5)	5 (33.3)	0.311	
Anemia	34 (57.6)	22 (50.0)	12 (80.0)	0.068	
Thrombocytopenia	14 (23.7)	6 (13.6)	8 (53.3)	0.002	
Osteomyelitis	11 (18.6)	10 (22.7)	1 (6.7)	0.259	
Stroke/ Cerebritis	15 (25.4)	2 (4.5)	13 (86.7)	< 0.0001	

Table 7: Relative risk of death in Mucormycosis patients

	Relative risk (95% CI)	p-value
Age > 60 years (Ref: ≤ 60 years)	2.162 ((0.9300, 5.0251)	0.098
Male (Ref: Female)	0.702 (0.2708, 1.8205)	0.506
Diabetes Mellitus (Ref: Diabetic)	(, , , , , , , , , , , , , , , , , , ,	
Newly diagnosed/ pre-diabetic	0.353 (0.0887, 1.4048)	0.052
COVID-19 related factors	,	
HRCT score ≥ 18 (Ref: < 18)	3.438 (1.6153, 7.3155)	0.017
Irrational use of steroids (Ref: Rational use)	0.689 (0.2875, 1.6530)	0.407
Not vaccinated against COVID-19 (Ref: vaccinated)	1.130 (0.3743, 3.4139)	0.822
Duration between 1st COVID-19 test and Mucormycosis diagnosis ≥ 15 days (Ref: <15 days)	0.892 (0.3670, 2.1676)	0.803
Duration between COVID-19 discharge and Mucormycosis admission ≥ 15 days (Ref: <15 days)	0.671 (0.1764, 2.5556)	0.544
Type of Mucormycosis (Ref: Rhino only)		
Rhinal + Orbital	0.455 (0.0690, 3.0048)	0.259
Rhinal + Orbital + Cerebral	5.440 (1.7140, 17.2662)	0.0004
Symptoms of Mucormycosis (Ref: No symptom)		
Facial pain	0.810 (0.3246, 2.0187)	0.663
Facial swelling	2.167 (0.7794, 6.0234)	0.098
Headache	1.023 (0.3802, 2.7539)	0.964
Eye swelling	5.121 (1.2665, 20.7087)	0.002
Eye pain	4.138 (1.3003, 13.1684)	0.003
Loss of vision	7.238 (2.2978, 22.8006)	< 0.0001
Ptosis	3.619 (1.4252, 9.1899)	0.005
Deviation of angle of mouth	1.662 (0.5140, 5.3715)	0.482
Nasal discharge	0.451 (0.1148, 1.7733)	0.146
Limb weakness	3.927 (1.9784, 7.7961)	0.001
Toothache	0.296 (0.0932, 0.9422)	0.012
Investigations in Mucormycosis		
Diabetic Ketoacidosis (Ref: No)	3.267 (1.5012, 7.1085)	0.011
Blood urea level	1.023 (1.0013, 1.0452)	0.0002
$ALC \ge 1000 \text{ (Ref: } < 1000)$	0.379 (0.1531, 0.9422)	0.065
Procalcitonin > 2 (Ref: ≤ 2)	1.507 (0.5467, 4.1513)	0.460
C-reactive Protein ≥ 50 (Ref: < 50)	3.438 (0.4949, 23.8759)	0.063
Ferritin > 1000 (Ref: ≤ 1000)	2.436 (0.7011, 8.4634)	0.153
D-Dimer > 252 (Ref: \leq 252)	1.286 (0.3315, 4.9860)	0.697
Treatment days in Mucormycosis (Ref: ≤ 21 days)		
Total Amphotericin days > 21 days	0.125 (0.0172, 0.9093)	0.002
Posaconazole > 21 days	0.364 (0.1293, 1.0228)	0.055
Complications in Mucormycosis (Ref: No complication)		
Hepatitis	2.229 (0.9437, 5.2628)	0.079
Thrombophlebitis	0.457 (0.1872, 1.1164)	0.083
Anemia	2.941 (0.9267, 9.3351)	0.067

	Thrombocytopenia	3.674 (1.6211, 8.3244)	0.004
	Stroke/ Cerebritis	19.067 (4.8522, 74.9224)	< 0.0001
895	ALC- Absolute lymphocyte count		

ALC- Absolute lymphocyte count




Figure 1: Prevalence of risk factors in Mucormycosis patients who died




Figure 1: Prevalence of risk factors in Mucormycosis patients who died